In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or maybe the contributors are unable to tolerate the study drugs. Probable new methods for that analysis and treatment of AML. (A) The identification https://abbv-744safetyandsideeffe13467.qodsblog.com/31938520/considerations-to-know-about-is-abbv-744-effective-for-hematologic-cancers